To Bleed or Not to Bleed - Anticoagulation in Patients with Non-valvular Atrial Fibrillation and End Stage Renal Disease

To Bleed or Not to Bleed - Anticoagulation in Patients with Non-valvular Atrial Fibrillation and End Stage Renal Disease

Save Big on Coursera Plus. 7,000+ courses at $160 off. Limited Time Only! Grab it Explore a comprehensive grand rounds presentation from Yale Cardiovascular Medicine where clinical fellows Dr. Maxwell Eder and Dr. Gregory Rubinfeld examine the complex decision-making process surrounding anticoagulation in patients with atrial fibrillation and end-stage renal disease. Delve into patient selection criteria and gain insights into emerging trends and future directions in managing this challenging patient population. Learn about the benefits and risks of anticoagulation therapy, helping to inform clinical decision-making for these high-risk patients.